SynthesisFrontiers in medicine2026
Efficacy of reduced-intensity or no heparin versus standard heparin anticoagulation in patients on extracorporeal membrane oxygenation: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the efficacy of reduced-intensity or no heparin anticoagulation strategy in comparison to standard anticoagulation strategy during extracorporeal membrane oxygenation (ECMO) support. Materials and methods: Systematic literature review and meta-analysis, complying with the PRISMA guidelines (PROSPERO-CRD42025633878). Results: Eleven studies comprising 958 patients were included in the analysis. Four studies included only patients treated with veno-venous extracorporeal membrane oxygenation (V-V ECMO) for acute respiratory distress syndrome or respiratory failure, two studies focused exclusively on patients treated with veno-arterial extracorporeal membrane oxygenation (V-A ECMO), and five studies included a mixture of patients with both modalities. Most studies ( Conclusion: Reduced-intensity or no heparin anticoagulation appears to be a feasible and safe strategy, demonstrating the potential to reduce bleeding complications without a significant increase in thrombotic events, and may be associated with improved patient outcomes. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633878, identifier CRD42025633878.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.